Funding
Series B · Biotech

WhiteLab Genomics raises $26m Series B led by AVP

WhiteLab Genomics uses AI to design genetic medicines and develop bio-assets for cell, RNA and DNA therapies.

Updated Oct 16, 2026By RoundOS Funding desk

WhiteLab Genomics raised $26 million in Series B funding led by AVP, with Blast Club, Debiopharm Innovation Fund, Omnes Capital and Yaday Health participating.

The company develops AI-designed bio-assets for cell, RNA and DNA therapies, connecting computational design with experimental validation. Its programmes are advancing towards in-vivo validation.

Funding history

Series B · This round$26M

Sources

  1. WhiteLab Genomics raises $26 Million — AVPavpcap.com · Oct 6, 2026
  2. startupdb.com

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
SEGNOS

SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.

UndisclosedPre-Series A · Oct 22, 2026

Related